Risk of bias assessment is a mandatory step in any systematic review or meta-analysis, and the summary visualization is one of the most scrutinized figures in your manuscript. The standard tool for generating these charts is robvis, an R package developed by McGuinness and Higgins (2021). The problem: robvis requires R, RStudio, and comfort with command-line package installation, which excludes the majority of clinical researchers who have never written a line of code.
This guide shows you how to create identical robvis-style charts using our free online tools, with no installation and no code. You will also learn how to handle multi-tool reviews, QUADAS-2 assessments, color coding standards, export specifications, and common visualization mistakes that trigger reviewer criticism.
Start with our free risk of bias rating tool for randomized controlled trials and our non-randomised RoB tool for non-randomized studies.
Keep the underlying judgements in the bias assessment templates.
Traffic Light Plot vs Summary Bar Chart: When to Use Each
Every risk of bias visualization falls into one of two categories, and most published systematic reviews include both.
The traffic light plot shows every included study as a row, with colored circles in each domain column (green for low risk, yellow for some concerns, red for high risk). This chart is essential when your review includes fewer than 15 studies, because reviewers want to see exactly which studies carry weaknesses and in which domains.
The weighted summary bar chart aggregates judgments across all studies and shows the percentage in each risk category per domain as horizontal stacked bars. This is the primary figure for reviews with 15 or more studies, where a traffic light plot would become too tall to read.
When to use which. Reviews with 10 or fewer studies need the traffic light plot alone. For 10 to 20 studies, present both. For more than 20, lead with the bar chart and place the traffic light plot in supplementary files. Many journals following Cochrane Handbook guidance expect both regardless of study count.
How Robvis Works and Why Researchers Need Alternatives
Robvis is an R package that generates risk of bias visualizations from structured CSV data. To use it, you must install R, load the package, format your data with specific column conventions, and run plotting functions. The output is a ggplot2 figure exportable as PDF or PNG.
The quality of robvis output is excellent. The problem is accessibility. Fewer than 30% of health sciences researchers have working knowledge of R. Common failure points include package dependency conflicts, outdated R versions that break installation, and confusion about data formatting requirements.
Our free RoB 2 assessment tool produces charts visually identical to robvis output, using the same color scheme, layout conventions, and domain structures defined in Sterne et al. (2019) for Cochrane RoB 2. Everything happens in your browser: enter study names, click radio buttons for each domain judgment, and the chart renders instantly.
For researchers who do use R, our tools also generate downloadable R scripts that reproduce the exact same chart using robvis, giving you instant browser-based visualization for drafting plus a reproducible script for supplementary materials.
Step-by-Step Walkthrough Using Research Gold's Free RoB Tool
Here is the complete workflow for creating a risk of bias summary chart online using our free tool.
Step 1: Choose your assessment framework. Open the online RoB tool for randomized controlled trials assessed with Cochrane RoB 2, or open the ROBINS-I Tool for non-randomized studies.
Step 2: Add your studies. Click "Add Study" and enter the first author and year for each included study (for example, "Smith 2022"). The tool supports up to 50 studies per chart.
Step 3: Rate each domain. For each study, select the risk of bias judgment in every domain. For RoB 2, you will rate five domains: randomization process, deviations from intended interventions, missing outcome data, measurement of the outcome, and selection of the reported result. The tool automatically calculates the overall judgment following the algorithm in the RoB 2 guidance document.
Step 4: Review the auto-generated chart. As you enter judgments, the traffic light plot and summary bar chart update in real time.
Step 5: Download your charts. Click the export button to download both charts as high-resolution PNG files sized for direct manuscript insertion.
The entire process takes approximately 5 to 10 minutes for a review with 10 to 15 studies, compared to 30 to 60 minutes for the equivalent robvis workflow including setup time.
RoB 2 for Randomized Controlled Trials
The Cochrane RoB 2 tool, described in Sterne et al. (2019), evaluates five bias domains: randomization process, deviations from intended interventions, missing outcome data, measurement of the outcome, and selection of the reported result. Key thresholds include flagging studies with more than 20% missing outcome data, checking trial registries for outcome switching (D5), and noting that blinding matters most for subjective outcomes like pain scores (D4). For a deeper walkthrough of every signaling question, see our complete RoB 2 assessment guide.
ROBINS-I for Non-Randomized Studies
ROBINS-I assesses seven domains using a four-level scale: Low, Moderate, Serious, or Critical risk of bias. The framework covers confounding, selection of participants, classification of interventions, deviations from intended interventions, missing data, measurement of outcomes, and selection of reported results.
Open our online ROBINS-I tool and follow the same sequence: add studies, rate each domain, and download the summary chart. For the complete walkthrough, see our ROBINS-I assessment guide.
The most common error with ROBINS-I is conflating "moderate risk" with "some concerns" from RoB 2. In ROBINS-I, moderate risk is the expected baseline for well-conducted observational studies, because some confounding is inherent. "Low risk" in ROBINS-I is rare and indicates the study is comparable to a well-performed randomized trial.
